Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 8/20 | 0.62 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.62 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.62 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15511844 | 0.84 | AVPR1B (0.68) | OXTRAVPR1BAVPR1AAVPR2 | |
| SCHEMBL14008026 | 0.80 | OXTR (0.73) | OXTRAVPR1BAVPR1AAVPR2 | |
| SCHEMBL22333508 | 0.80 | OXTR (0.77) | OXTRAVPR1BAVPR1AAVPR2 | |
| SCHEMBL29367334 | 0.79 | AVPR1A (0.89) | OXTRAVPR1BAVPR1AAVPR2PTGS1 | |
| SCHEMBL15511438 | 0.79 | OXTR (0.87) | OXTRAVPR1BAVPR1AAVPR2PTGS1 | |
| SCHEMBL30525288 | 0.79 | AVPR1A (0.89) | OXTRAVPR1BAVPR1AAVPR2PTGS1 | |
| SCHEMBL29934390 | 0.79 | AVPR1A (0.89) | OXTRAVPR1BAVPR1AAVPR2PTGS1 | |
| Ornipressin SCHEMBL296322 | 0.79 | AVPR1A (0.88) | OXTRAVPR1BAVPR1AAVPR2PTGS1 | |
| Ornipressin SCHEMBL1650220 | 0.79 | AVPR1A (0.88) | OXTRAVPR1BAVPR1AAVPR2PTGS1 | |
| SCHEMBL23382250 | 0.79 | OXTR (0.73) | OXTRAVPR1BAVPR1AAVPR2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210077568-A1 | PEPTIDE CONGENERS WITH POLYMER EXCIPIENTS | ENDO OPERATIONS LIMITED (IE) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077568-A1 | PEPTIDE CONGENERS WITH POLYMER EXCIPIENTS | IAPP, VIP, NGLY1 | OXTR 348/4885AVPR1B 93/4885AVPR1A 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.